Day: March 1, 2023

Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial Kevzara now approved to treat two chronic inflammatory disorders TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara® (sarilumab) for the treatment of polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. “Polymyalgia rheumatica can be an incapacitating disease, causing painful disease flares in multiple parts of the body that leave people fatigued and unable to fully perform everyday activities. Corticosteroids have been the...

TORONTO, Feb. 28, 2023 (GLOBE NEWSWIRE) — Dynamic Technologies Group Inc. (TSXV: DTG, OTC:ERILF) (“Dynamic”, “Company”, “we” and “our”) with reference to our prior new release dated August 8, 2022 announces that its USD$16 million senior secured credit facilities with Promising Expert Limited (“PEL”) matured on February 28, 2023 (the “PEL Credit Facilities”) and the Company is currently in default for non-payment of the same. The default under the PEL Credit Facilities constitutes a cross-default under the terms of the Company’s USD$2 million subordinated secured loan with Export Development Canada (“EDC”). The Company is having ongoing discussions with PEL, who remains supportive of the Company. Based on those discussions, the Company does not expect PEL to issue a demand for payment at this time or to take any immediate steps...